Molecular Origami: Start-Ups Tackle Protein Folding
This article was originally published in Start Up
Start-ups are developing novel therapeutics that work by shepherding faulty proteins into their normal conformations. The risky approach, if successful, could dramatically increase the pharmaceutical arsenal. Drug companies remain skeptical, prefering to wait for clinical validation of the existing compounds before inking big deals.
You may also be interested in...
Emerging Company Profile: The Phase III success of Pfizer's tafamidis means Eidos’ protein misfolding drug AG10 is not the first – but it is validated and differentiated, says BridgeBio-backed start-up Eidos.
Researchers have shown that a new class of small molecule can inhibit assembly of the protein alpha-synuclein into toxic clumps, a hallmark of Parkinson’s disease. Their work supports other ongoing investigations suggesting that the compound may be useful as a neuroprotective agent for treating a range of diseases characterized by the clumping of amyloid proteins, including Alzheimer’s disease, various types of amyloidosis, and prion disease.
Four start-ups previously profiled in START-UP – CoMentis, EnVivo Pharmaceuticals, Avid Radiopharmaceuticals and AC Immune SA – show how some biotechs have successfully ridden through the rough patches any company brave enough to tackle Alzheimer’s disease will likely face.